Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Incubation with sodium nitrite attenuates fatigue development in intact single mouse fibres at physiological P O 2 .

Bailey SJ, Gandra PG, Jones AM, Hogan MC, Nogueira L.

J Physiol. 2019 Sep 21. doi: 10.1113/JP278494. [Epub ahead of print]

PMID:
31541562
2.

Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease.

Sanchis IM, Shukoor S, Irazabal MV, Madsen CD, Chebib FT, Hogan MC, El-Zoghby Z, Harris PC, Huston J, Brown RD, Torres VE.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1151-1160. doi: 10.2215/CJN.14691218. Epub 2019 Jul 30.

PMID:
31362991
3.

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.

Martin WP, Vaughan LE, Yoshida K, Takahashi N, Edwards ME, Metzger A, Senum SR, Masyuk TV, LaRusso NF, Griffin MD, El-Zoghby Z, Harris PC, Kremers WK, Nagorney DM, Kamath PS, Torres VE, Hogan MC.

Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):149-159. doi: 10.1016/j.mayocpiqo.2019.03.004. eCollection 2019 Jun.

4.

Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in Autosomal Dominant Polycystic Kidney Disease.

McNicholas BA, Kotaro Y, Martin W, Sharma A, Kamath PS, Edwards ME, Kremers WK, Chari ST, Torres VE, Harris PC, Takahashi N, Hogan MC.

Pancreas. 2019 May/Jun;48(5):698-705. doi: 10.1097/MPA.0000000000001306.

PMID:
31091218
5.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):910.

6.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

7.

Environmental Factors: Macroenvironment versus Microenvironment.

Hogan MC, Norton JN, Reynolds RP.

In: Weichbrod RH, Thompson GAH, Norton JN, editors. Management of Animal Care and Use Programs in Research, Education, and Testing. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2018. Chapter 20.

8.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

9.

DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.

Nasr SH, Vrana JA, Dasari S, Bridoux F, Fidler ME, Kaaki S, Quellard N, Rinsant A, Goujon JM, Sethi S, Fervenza FC, Cornell LD, Said SM, McPhail ED, Herrera Hernandez LP, Grande JP, Hogan MC, Lieske JC, Leung N, Kurtin PJ, Alexander MP.

Kidney Int Rep. 2017 Aug 8;3(1):56-64. doi: 10.1016/j.ekir.2017.07.017. eCollection 2018 Jan.

10.

A mitochondrial-targeted antioxidant improves myofilament Ca2+ sensitivity during prolonged low frequency force depression at low PO2.

Gandra PG, Shiah AA, Nogueira L, Hogan MC.

J Physiol. 2018 Mar 15;596(6):1079-1089. doi: 10.1113/JP275470. Epub 2018 Feb 11.

11.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

12.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies.

Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE.

Kidney Int Rep. 2017 Jun 6;2(5):913-923. doi: 10.1016/j.ekir.2017.05.014. eCollection 2017 Sep.

13.

Delayed Methotrexate Clearance Despite Carboxypeptidase-G2 (Glucarpidase) Administration in 2 Patients With Toxic Methotrexate Levels.

Wyatt KD, Cooper J, Scott K, Broomall E, Altaf S, Hogan MC, Rodriguez V, Khan S.

J Pediatr Hematol Oncol. 2018 Mar;40(2):152-155. doi: 10.1097/MPH.0000000000001058.

PMID:
29240024
14.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

15.

Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice.

Safadi S, Albright RC Jr, Dillon JJ, Williams AW, Alahdab F, Brown JK, Severson AL, Kremers WK, Ryan MA, Hogan MC.

Kidney Int Rep. 2017 Mar 16;2(4):695-704. doi: 10.1016/j.ekir.2017.03.003. eCollection 2017 Jul.

16.

The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression.

Neijenhuis MK, Kievit W, Perrone RD, Sloan JA, Erwin P, Murad MH, Gevers TJG, Hogan MC, Drenth JPH.

BMC Nephrol. 2017 May 25;18(1):169. doi: 10.1186/s12882-017-0578-6. Review.

17.

Overview of The Journal of Physiology Special Issue on the 'Biomedical basis of elite performance'.

Hogan MC, Powers SK.

J Physiol. 2017 May 1;595(9):2769-2770. doi: 10.1113/JP273978. No abstract available.

18.

[Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER Statement].

Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Marušic A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; Grupo de trabalho GATHER.

Epidemiol Serv Saude. 2017 Jan-Mar;26(1):215-222. doi: 10.5123/S1679-49742017000100023. Portuguese.

19.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

20.

No Muscle Is an Island: Integrative Perspectives on Muscle Fatigue.

Kent JA, Ørtenblad N, Hogan MC, Poole DC, Musch TI.

Med Sci Sports Exerc. 2016 Nov;48(11):2281-2293. Review.

PMID:
27434080
21.

Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome.

Said SM, Fidler ME, Valeri AM, McCann B, Fiedler W, Cornell LD, Alexander MP, Alkhunaizi AM, Sullivan A, Cramer CH, Hogan MC, Nasr SH.

Kidney Int Rep. 2016 Sep 29;2(1):44-52. doi: 10.1016/j.ekir.2016.09.056. eCollection 2017 Jan.

22.

Evaluating safety of tunneled small bore central venous catheters in chronic kidney disease population: A quality improvement initiative.

Bhutani G, El Ters M, Kremers WK, Klunder JL, Taler SJ, Williams AW, Stockland AH, Hogan MC.

Hemodial Int. 2017 Apr;21(2):284-293. doi: 10.1111/hdi.12484. Epub 2016 Sep 20.

PMID:
27647824
23.

Exercise and oxidative stress.

Powers SK, Hogan MC.

J Physiol. 2016 Sep 15;594(18):5079-80. doi: 10.1113/JP272255. No abstract available.

24.

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC.

Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12.

25.

Correction: Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.

Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Marušić A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; GATHER Working Group.

PLoS Med. 2016 Aug 9;13(8):e1002116. doi: 10.1371/journal.pmed.1002116. eCollection 2016 Aug.

26.

Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.

Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Marušić A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; (The GATHER Working Group).

Lancet. 2016 Dec 10;388(10062):e19-e23. doi: 10.1016/S0140-6736(16)30388-9. Epub 2016 Jun 28. Review.

27.

Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement.

Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Marušić A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; GATHER Working Group.

PLoS Med. 2016 Jun 28;13(6):e1002056. doi: 10.1371/journal.pmed.1002056. eCollection 2016 Jun. Erratum in: PLoS Med. 2016 Aug;13(8):e1002116.

28.

Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.

Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE; Genkyst Study Group, HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2016 Jun 2;98(6):1193-1207. doi: 10.1016/j.ajhg.2016.05.004.

29.

Skeletal myofiber VEGF regulates contraction-induced perfusion and exercise capacity but not muscle capillarity in adult mice.

Knapp AE, Goldberg D, Delavar H, Trisko BM, Tang K, Hogan MC, Wagner PD, Breen EC.

Am J Physiol Regul Integr Comp Physiol. 2016 Jul 1;311(1):R192-9. doi: 10.1152/ajpregu.00533.2015. Epub 2016 May 25.

30.

Reclassifying causes of obstetric death in Mexico: a repeated cross-sectional study.

Hogan MC, Saavedra-Avendano B, Darney BG, Torres-Palacios LM, Rhenals-Osorio AL, Sierra BL, Soliz-Sánchez PN, Gakidou E, Lozano R.

Bull World Health Organ. 2016 May 1;94(5):362-369B. doi: 10.2471/BLT.15.163360. Epub 2016 May 2.

31.

Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease.

Chebib FT, Harmon A, Irazabal Mira MV, Jung YS, Edwards ME, Hogan MC, Kamath PS, Torres VE, Nagorney DM.

J Am Coll Surg. 2016 Jul;223(1):118-126.e1. doi: 10.1016/j.jamcollsurg.2015.12.051. Epub 2016 Jan 14.

32.

Polycystic Liver Disease: The Benefits of Targeting cAMP.

Larusso NF, Masyuk TV, Hogan MC.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1031-4. doi: 10.1016/j.cgh.2016.03.008. Epub 2016 Mar 10. No abstract available.

33.

Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.

Neijenhuis MK, Gevers TJ, Hogan MC, Kamath PS, Wijnands TF, van den Ouweland RC, Edwards ME, Sloan JA, Kievit W, Drenth JP.

Hepatology. 2016 Jul;64(1):151-60. doi: 10.1002/hep.28545. Epub 2016 Apr 15.

34.

Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.

Chebib FT, Jung Y, Heyer CM, Irazabal MV, Hogan MC, Harris PC, Torres VE, El-Zoghby ZM.

Nephrol Dial Transplant. 2016 Jun;31(6):952-60. doi: 10.1093/ndt/gfw008. Epub 2016 Feb 29.

35.

A case report of sevelamer-associated recto-sigmoid ulcers.

Tieu C, Moreira RK, Song LM, Majumder S, Papadakis KA, Hogan MC.

BMC Gastroenterol. 2016 Feb 24;16:20. doi: 10.1186/s12876-016-0441-4.

36.

Cytosolic calcium transients are a determinant of contraction-induced HSP72 transcription in single skeletal muscle fibers.

Stary CM, Hogan MC.

J Appl Physiol (1985). 2016 May 15;120(10):1260-6. doi: 10.1152/japplphysiol.01060.2015. Epub 2016 Feb 11.

37.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

38.

Strategy and rationale for urine collection protocols employed in the NEPTUNE study.

Hogan MC, Lieske JC, Lienczewski CC, Nesbitt LL, Wickman LT, Heyer CM, Harris PC, Ward CJ, Sundsbak JL, Manganelli L, Ju W, Kopp JB, Nelson PJ, Adler SG, Reich HN, Holzmann LB, Kretzler M, Bitzer M.

BMC Nephrol. 2015 Nov 17;16:190. doi: 10.1186/s12882-015-0185-3.

39.

Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.

Gevers TJ, Nevens F, Torres VE, Hogan MC, Drenth JP.

Liver Int. 2016 Apr;36(4):595-602. doi: 10.1111/liv.12986. Epub 2015 Nov 9.

40.

Closeout of the HALT-PKD trials.

Moore CG, Spillane S, Simon G, Maxwell B, Rahbari-Oskoui FF, Braun WE, Chapman AB, Schrier RW, Torres VE, Perrone RD, Steinman TI, Brosnahan G, Czarnecki PG, Harris PC, Miskulin DC, Flessner MF, Bae KT, Abebe KZ, Hogan MC.

Contemp Clin Trials. 2015 Sep;44:48-55. doi: 10.1016/j.cct.2015.07.017. Epub 2015 Jul 29.

41.

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.

Hogan MC, Masyuk T, Bergstralh E, Li B, Kremers WK, Vaughan LE, Ihrke A, Severson AL, Irazabal MV, Glockner J, LaRusso NF, Torres VE.

Mayo Clin Proc. 2015 Aug;90(8):1030-7. doi: 10.1016/j.mayocp.2015.05.011. Epub 2015 Jul 9.

42.

Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.

Neijenhuis MK, Gevers TJ, Nevens F, Hogan MC, Torres VE, Kievit W, Drenth JP.

Aliment Pharmacol Ther. 2015 Sep;42(5):591-8. doi: 10.1111/apt.13301. Epub 2015 Jul 1.

43.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670
44.

Identification of Biomarkers for PKD1 Using Urinary Exosomes.

Hogan MC, Bakeberg JL, Gainullin VG, Irazabal MV, Harmon AJ, Lieske JC, Charlesworth MC, Johnson KL, Madden BJ, Zenka RM, McCormick DJ, Sundsbak JL, Heyer CM, Torres VE, Harris PC, Ward CJ.

J Am Soc Nephrol. 2015 Jul;26(7):1661-70. doi: 10.1681/ASN.2014040354. Epub 2014 Dec 4.

45.

Blood pressure in early autosomal dominant polycystic kidney disease.

Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2255-66. doi: 10.1056/NEJMoa1402685. Epub 2014 Nov 15.

46.

Angiotensin blockade in late autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; HALT-PKD Trial Investigators.

N Engl J Med. 2014 Dec 11;371(24):2267-76. doi: 10.1056/NEJMoa1402686. Epub 2014 Nov 15.

47.

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Casteleijn NF, Visser FW, Drenth JP, Gevers TJ, Groen GJ, Hogan MC, Gansevoort RT; DIPAK Consortium.

Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv142-53. doi: 10.1093/ndt/gfu073. Review.

48.

Recovery of Indicators of Mitochondrial Biogenesis, Oxidative Stress, and Aging With (-)-Epicatechin in Senile Mice.

Moreno-Ulloa A, Nogueira L, Rodriguez A, Barboza J, Hogan MC, Ceballos G, Villarreal F, Ramirez-Sanchez I.

J Gerontol A Biol Sci Med Sci. 2015 Nov;70(11):1370-8. doi: 10.1093/gerona/glu131. Epub 2014 Aug 20.

49.

Liver involvement in early autosomal-dominant polycystic kidney disease.

Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW.

Clin Gastroenterol Hepatol. 2015 Jan;13(1):155-64.e6. doi: 10.1016/j.cgh.2014.07.051. Epub 2014 Aug 9.

50.

Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials.

Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE; CRISP Investigators.

J Am Soc Nephrol. 2015 Jan;26(1):160-72. doi: 10.1681/ASN.2013101138. Epub 2014 Jun 5.

Supplemental Content

Loading ...
Support Center